Hyperthermia and thermochemotherapy

  • Rolf D. Issels
Part of the Cancer Treatment and Research book series (CTAR, volume 67)


The combination of anticancer drugs with hyperthermia was only recently introduced as an experimental clinical strategy. This approach within the field of medical oncology is based on the convincing evidence that hyperthermia enhances the therapeutic effect of several chemotherapeutic agents, even in drug-resistant cells. Such a combined modality is of particular interest as a means of overcoming the limited therapeutic efficacy of conventional anticancer agents in the case of large, resistant human tumors.


Isolate Limb Perfusion Tumor Temperature Advanced Soft Tissue Sarcoma Thermal Enhancement Whole Body Hyperthermia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hahn GM: Hyperthermia and Cancer. New York: Plenum Press, 1982.CrossRefGoogle Scholar
  2. 2.
    Marmor JB: Interactions of hyperthermia and chemotherapy in animals. Cancer Res 39:2269–2276, 1979.PubMedGoogle Scholar
  3. 3.
    Engelhardt R: Hyperthermia and drugs. Recent Res Cancer Res 104:136–203, 1987.CrossRefGoogle Scholar
  4. 4.
    Dahl O: Interaction of hyperthermia and chemotherapy. Recent Res Cancer Res 107:157–169, 1988.CrossRefGoogle Scholar
  5. 5.
    Wallner KE, Li GC: Adriamycin resistance, heat resistance and radiation response in Chinese hamster fibroblasts. Int J Radiat Oncol Biol Phys 12:829–833, 1986.PubMedCrossRefGoogle Scholar
  6. 6.
    Bates DA, Mackillop WJ: Hyperthermia, adriamycin transport and cytotoxicity in drug-sensitive and-resistant Chinese hamster ovary cells. Cancer Res 46:5477–5481, 1986.PubMedGoogle Scholar
  7. 7.
    Wallner KE, deGregorio MW, Li GC: Hyperthermia potentiation of cis-diamminedichloro-platinum (11) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res 46:6242–6245, 1986.PubMedGoogle Scholar
  8. 8.
    Wallner KE, Banda M, Li GC: Hyperthermic enhancement of cell killing by mitomycin C in mitomycin C-resistant Chinese hamster ovary cells. Cancer Res 47:1308–1312, 1987.PubMedGoogle Scholar
  9. 9.
    Pinedo HM, Bramwell VHC, Mouridsen HT, et al.: Chemotherapy of advanced soft tissue sarcoma in adults. Cancer Treat Rev 4:67–86, 1977.PubMedCrossRefGoogle Scholar
  10. 10.
    O’Brian RM, Baker LH, Gottlieb JE, et al.: Dose response evaluation of doxorubicin in human neoplasia. Cancer 39:1940–1948, 1976.CrossRefGoogle Scholar
  11. 11.
    Hahn GM, Strande DP: Cytotoxic effects of hyperthermia and adriamycin on Chinese hamster cells, J Natl Cancer Inst 57:1063–1067, 1976.PubMedGoogle Scholar
  12. 12.
    Dahl O: Interaction of hyperthermia and doxorubicin on a malignant, neurogenic rat cell line (BT4C) in culture. J Natl Cancer Inst 61:251–253, 1982.Google Scholar
  13. 13.
    Calabro A, Singletary E, Tucker S, et al.: In vitro thermo-chemosensitivity screening of spontaneous human tumors: significant potentiation for cisplatin but not adriamycin. Int J Cancer 43:385–390, 1989.PubMedCrossRefGoogle Scholar
  14. 14.
    Akiyoshi T, Wanda T, Arinaga S, et al.: Enhanced chemosensitivity of cells from malignant effusions under condition of exposure to high temperature. Jpn J Surg 16:323–329, 1989.CrossRefGoogle Scholar
  15. 15.
    Stuart-Harris RC, Harper PG, Parsons CA, et al.: High dose alkylating therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma. Cancer Chemother Pharmacol 11:69, 1983.PubMedCrossRefGoogle Scholar
  16. 16.
    Bramwell VHC, Mouridsen HT, Santoro A, et al.: Cyclophosfamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcoma. Eur J Cancer 23:311, 1987.CrossRefGoogle Scholar
  17. 17.
    Schutte J, Mouridsen HT, Steward WP, et al.: Adriamycin plus ifosfamide in previously untreated patients with soft tissue sarcomas. Eur J Cancer 26:558, 1990.PubMedCrossRefGoogle Scholar
  18. 18.
    Wiedemann G, Roszinski S, Biersack A, et al.: Local hyperthermia enhances cyclophosfamide, ifosfamide and cis-diamminedichloroplatinum cytotoxicity on human-derived breast carcinoma and sarcoma xenografts in nude mice. J Cancer Res Clin Oncol 118:129–135, 1982.CrossRefGoogle Scholar
  19. 19.
    Wiedemann G, Knocks D, Mentzel M, et al.: Effects of temperature on the therapeutic efficacy and pharmacokinetics of ifosfamide. Cancer Res. In press, 1993.Google Scholar
  20. 20.
    Voth B, Sauer HJ, Wilmanns W: Thermostability of cytostatic drugs in vitro and thermo-sensitivity of cultured human lymphoblasts against cytostatic drugs. Recent Res Cancer Res 107:170–176, 1988.CrossRefGoogle Scholar
  21. 21.
    Santoro A, Rouesse J, Steward W, et al.: A radomized EORTC study in advanced soft tissue sarcomas (STS): ADM versus ADM + IFO versus CYVADIC. Proc Am Soc Clin Oncol 9:309, 1990.Google Scholar
  22. 22.
    Elias A, Ryan L, Sulkes A, et al.: Response to mesna, doxorubicin, ifosfamide and dacarbacine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7:1208–1216, 1989.PubMedGoogle Scholar
  23. 23.
    Bramwell V, Quirt I, Warr D, et al.: Combination chemotherapy with doxorubicin, dacarbacine, and ifosfamide in advanced adult soft tissue sarcomas. J Natl Cancer Inst 81:1496–1499, 1989.PubMedCrossRefGoogle Scholar
  24. 24.
    Gottlieb JA, Baker LH, O’Brian RM, et al.: Adriamycin (NSC-123127), used alone and in combination for soft tissue and bony sarcomas. Cancer Chemother Rep 6:271–282, 1975.Google Scholar
  25. 25.
    Lopez M, Carpano S, Di Lauro L, et al.: Epirubicin ad DTIC (EDIC) for advanced soft-tissue sarcomas. Oncology 48:230–233, 1991.PubMedCrossRefGoogle Scholar
  26. 26.
    Hahn GM: Potential for therapy of drugs and hyperthermia. Cancer Res 39:2264–2268, 1979.PubMedGoogle Scholar
  27. 27.
    Dahl O: Hyperthermic potentiation of doxorubicin and 4’-epi-doxorubicin in a transplantable neurogenic rat tumor (BT4A) in BD IX rats. J Radiat Oncol Biol Phys 9:203–207, 1983.CrossRefGoogle Scholar
  28. 28.
    Donaldson SS, Gordon LF, Hahn GM: Protective effect of hyperthermia against the cytotoxicity of actinomycin D on Chinese hamster cells. Cancer Treat Rep 62:1489–1495, 1978.PubMedGoogle Scholar
  29. 29.
    Hahn GM, Shiu EC: Effect of pH and elevated temperature on the cytotoxicity of same chemotherapeutic agents on Chinese hamster cells in vitro. Cancer Res 43:5789–5791, 1983.PubMedGoogle Scholar
  30. 30.
    Honess DJ, Donaldson J, Workman P, et al.: The effect of systemic hyperthermia in melphalan pharmacokinetics in mice. Br J Cancer 51:77–84, 1985.PubMedCrossRefGoogle Scholar
  31. 31.
    Honess DJ, Bleehen NM: Thermochemotherapy with cisplatinum CCNU, BCNU, chlo-rambucil and melphalan on murine marrow and two tumours: Therapeutic gain for melphalan only. Br J Radiat 58:63–72, 1985.CrossRefGoogle Scholar
  32. 32.
    Laskowitz DT, Elion GB, Dewhirst MW, et al.: Hyperthermia-induced enhancement of melphalan activity against human rhabdomyosacoma xenografts. Radiat Res. In press, 1993.Google Scholar
  33. 33.
    Alberts DS, Peng YM, Chen G, et al.: Therapeutic synergism of hyperthermia and cisplatin in a mouse tumor model. J Natl Cancer Inst 65:455–460, 1980.PubMedGoogle Scholar
  34. 34.
    Mean RG, Corry PM, Fletcher Se, et al.: Thermal enhancement of DNA damage in mammalian cells treated with cisdiamminedichloroplatinum (II). Cancer Res 40:1136–1139, 1980.Google Scholar
  35. 35.
    Douple EB, Strohbehn JW, di Sieyes DC, et al.: Therapeutic potentiation of cis-dichlordiammineplatinum and radiation by interstitial microwave hyperthermia in a mouse tumor. Natl Cancer Inst Monogr 61:259–262, 1982.Google Scholar
  36. 36.
    Herman LS, Sweets CC, White DM, et al.: Effect of heating on lethality due to hyperthermia and selected chemotherapeutic drugs. J Natl Cancer Inst 68:487–491, 1982.PubMedGoogle Scholar
  37. 37.
    Zakris EL, Dewhirst MW, Riviere JE, et al.: Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J Clin Oncol 5:1613–1620, 198PubMedGoogle Scholar
  38. 38.
    Miser JS, Kinsella TJ, Triche TJ, et al.: Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5:1191–1198, 1987.PubMedGoogle Scholar
  39. 39.
    Ikegami T, Kubota N, Watai K, et al.: The enhancement of hyperthermic effect by etoposide (VP-16) on rat hepatoma 3924A cells (abstract). Proc Int Hyperther Oncol (Kyoto) 13:186, 1988.Google Scholar
  40. 40.
    Pfeffer MR, Herman TS, Teicher BA, et al.: Preclinical studies of etoposide and cisdiamminedichloroplatinum (II) in combination with radiation and hyperthermia in the FSA IIc fibrosarcoma (abstract). Int J Radiat Oncol Biol Phys 17:180, 1989.CrossRefGoogle Scholar
  41. 41.
    Parks LC: Clinical evaluation: Induction of systemic hyperthermia by extracorporal circulation as primary and adjuvant treatment of advanced solid tumor malignancies. In Nussbaum GH, (ed). Physical Aspects of Hyperthermia. New York: American Institute of Physics, 1982, pp 660–632.Google Scholar
  42. 42.
    Robins HI, Dennis WH, Neville AJ, et al.: A nontoxic system for 41.8&#X00B0C whole body hyperthermia: Results of a Phase I study using a radiant heat device. Cancer Res 45:3937–3944, 1985.PubMedGoogle Scholar
  43. 43.
    Thrall DE, Page RL, Dewhirst MW, et al.: Temperature measurements in normal and tumor tissue of dogs undergoing whole body hyperthermia. Cancer Res 46:6229–6235, 1986.PubMedGoogle Scholar
  44. 44.
    Thrall Dr, Dewhirst MW, Page RL, et al.: A comparison of temperature in canine solid tumours during local and whole-body hyperthermia administered alone and simultaneously. Int J Hyperthermia, 6:305–317, 1990.PubMedCrossRefGoogle Scholar
  45. 45.
    Meyer JL, Van Kersen I, Becker B, et al.: The importance of thermotolerance after 41.0°C hyperthermia: In vitro and in vivo tumor and normal tissue investigations. Int J Radiat Oncol Biol Phys 11:973–981, 1985.PubMedCrossRefGoogle Scholar
  46. 46.
    Page RL, Meyer RE, Thrall DE, et al.: Cardiovascular and metabolic response of tumor bearing dogs to whole body hyperthermia. Int J Hyperthermia 3:513–525, 1987.PubMedCrossRefGoogle Scholar
  47. 47.
    Cronau LH Jr, Bourke DL, Bull JM: General anesthesia for whole body hyperthermia. Cancer Res 44(Suppl):4873–4877, 1984.Google Scholar
  48. 48.
    Robins HI: The role of whole body hyperthermia in the treatment of neoplastic disease, its current status and future prospects. Cancer Res 44:4878S–4883S, 1984.PubMedGoogle Scholar
  49. 49.
    Gerad H, Echo D, Whitacre M, et al.: Doxorubicin, cyclophosphamide, and whole body hyperthermia for treatment of advanced soft tissue sarcoma. Cancer 53:2585–2591, 1984.PubMedCrossRefGoogle Scholar
  50. 50.
    Engelhardt R, Neumann HA, Weth-Simon R, et al.: Randomized trial in small cell lung CA (SCLC) pts: chemotherapy (CT) without vs. with whole body hyperthermia (WBH). Abstract for the 34th Annual Meeting of the Radiation Research Society, 1986, p 16.Google Scholar
  51. 51.
    Jabboury K, Mansfield B, Bull JMC: Whole body hyperthermia (WBH) + BCNU in advanced sarcoma. Abstract for the 34th Annual Meeting of the Radiation Research Society, 1985, p 16.Google Scholar
  52. 52.
    Robins HI, Sielaff KM, Storer B, et al.: Phase I trial of human lymphoblastoid interferon with whole body hyperthermia in advanced cancer. Cancer Res 49:1609–1615, 1989.PubMedGoogle Scholar
  53. 53.
    Groveman DS, Borden EC, Merritt JA, et al.: Augmented antiproliferative effects on interferons at elevated temperatures. Cancer Res 44:5517–5521, 1984.PubMedGoogle Scholar
  54. 54.
    Willnow U, Lindner H, Brock D, et al.: Behandlung konventionell inkurabler Tumorerkrankungen im Kindesalter mit Ganzkörperhyperthermie und Chemotherapie. Dtsch Med Wschr 114:208–213, 1989.PubMedCrossRefGoogle Scholar
  55. 55.
    Maeta M, Koga S, Wada J, et al.: Clinical evaluation of total-body hyperthermia combined with anticancer chemotherapy for far-advanced miscellaneous cancer in Japan. Cancer 59:1101–1106, 1987.PubMedCrossRefGoogle Scholar
  56. 56.
    Truchetet F, Grosshans E, Kretz JC, et al.: Combined hyperthermia and chemotherapy for malignant melanoma of the limbs. In: Gautherie M, ed. Intersitital, endocavitary and perfusional hyperthermia. Berlin: Springer-Verlag, 1990.Google Scholar
  57. 57.
    Klopp CT, Alford TC, Bateman J, et al.: Fractionated intraarterial cancer chemotherapy with methyl-bis-amine hydrochloride: A preliminary report. Ann Surg 132:811–832, 1950.PubMedCrossRefGoogle Scholar
  58. 58.
    Creech O, Krementz ET, Ryan RF, et al.: Chemotherapy of cancer: Regional perfusion utilizing an extracorporal circuit. Ann Surg 148:616–632, 1958.PubMedCrossRefGoogle Scholar
  59. 59.
    Stehlin JS: Hyperthermic perfusion with chemotherapy for cancers of the extremity. Surg Gynecol Obstet 129:305–308, 1969.PubMedGoogle Scholar
  60. 60.
    Stehlin JS, De Ipolyi PD, Giovanella BC, et al.: Soft tissue sarcomas of the extremity. Am J Surg 130:643–646, 1975.PubMedCrossRefGoogle Scholar
  61. 61.
    Lethi PM, Moseley HS, Janoff K, et al.: Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 162:149–152, 1986.Google Scholar
  62. 62.
    Hoekstra, HJ, Schraffordt Koops H, Molenaar WM, et al.: Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities.Google Scholar
  63. 63.
    Lejeune FJ, Lienard D, Ewalenko P: Hyperthermic isolation perfusion of the limbs with cytostatics after surgical excision of sarcomas. World J Surg 12:345–348, 1988.PubMedCrossRefGoogle Scholar
  64. 64.
    Pommier RF, Moseley HS, Cohen J, et al.: Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft tissue sarcoma and melanoma of the extremities. Am J Surg 155:667–671, 1988.PubMedCrossRefGoogle Scholar
  65. 65.
    Di Filippo F, et al.: Role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities. World J Surg 12:332–339, 1988.PubMedCrossRefGoogle Scholar
  66. 66.
    Di Filippo F, Psaila G, Botti C, et al.: Hyperthermic antiblastic perfusion for limb sarcoma. Abstract presented at the International Meeting in Aviano (Italy), 1991, pp 78–82.Google Scholar
  67. 67.
    Meyers JL, Kapp DS, Fessenden P, et al.: Hyperthermic oncology: Current biology, physics and clinical results. Pharmac Ther 42:251–288, 1989.CrossRefGoogle Scholar
  68. 68.
    Turner PF: Regional hyperthermia with an annular phased array. IEEE Trans Biomed Eng 31:106–114, 1984.PubMedCrossRefGoogle Scholar
  69. 69.
    Samulski TV, Kapp DS, Fessenden P, et al.: Heating deep seated eccentrically located tumors with an annular phased array system: A comparative clinical study using two annular phased array operating configurations. Int J Radiat Oncol Biol Phys 7: 13:83–94, 1987.CrossRefGoogle Scholar
  70. 70.
    Gibbs FA: ‘Thermal mapping’ in experimental cancer treatment with hyperthermia: Description and use of a semiautomatic system. Int J Radiat Oncol Biol Phys 9:1057–1063, 1983.PubMedCrossRefGoogle Scholar
  71. 71.
    Sapozink MD, Gibbs FA, Egger MJ, et al.: Regional hyperthermia for clinically advanced deep-seated pelvic malignancy. Am J Clin Oncol 9:162–169, 1986.PubMedCrossRefGoogle Scholar
  72. 72.
    Issels RD, Wadepohl M, Tilling K, et al.: Regional hyperthermia combined with systemic chemotherapy in advanced abdominal and pelvic tumors: First results of a pilot study employing an annular phased array applicator. Recent Res Cancer Res 107:236–243, 1987.CrossRefGoogle Scholar
  73. 73.
    Issels RD, Prenninger SW, Nagele A, et al.: Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: A phase II study. J Clin Oncol 8:1818–1829, 1990.PubMedGoogle Scholar
  74. 74.
    Issels RD, Mittermüller J, Gerl A, et al.: Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: Updated report on 65 patients. J Cancer Res Clin Oncol 117(Suppl IV):S141–S147, 1991.PubMedCrossRefGoogle Scholar
  75. 75.
    Oleson JR, Dewhirst MW, Harrelson JM, et al.: Tumor temperature distributions predict hyperthermia effect. Int J Radiat Oncol Biol Phys 16:559–570, 1989.PubMedCrossRefGoogle Scholar
  76. 76.
    Leopold KA, Harrelson J, Prosnitz L, et al.: Preoperative hyperthermia and radiation of soft tissue sarcomas: Advantage of two vs. one hyperthermia treatments per week. Int J Radiat Oncol Bio Phys 16:107–115, 1989.CrossRefGoogle Scholar
  77. 77.
    Leopold KA, Dewhirst MW, Samulski T, et al.: Relationships among tumor temperature, treatment time, and histopathological outcome using preoperative hyperthermia with radiation in soft tissue sarcomas. Int J Radiat Oncol Biol Phys 22:989–998, 1992.PubMedCrossRefGoogle Scholar
  78. 78.
    Rouesse JG, Friedmann S, Sevin DM, et al.: Preoperative chemotherapy in the treatment of locally advanced soft tissue sarcomas. Cancer 60:296–300, 1987.PubMedCrossRefGoogle Scholar
  79. 79.
    Pezzi CM, Pollock RE, Evans HL, et al.: Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg 4:476–481, 1990.CrossRefGoogle Scholar
  80. 80.
    Issels RD, Bosse D, Abdel-Rahman S, et al.: Preoperative systemic EIA chemotherapy (etoposide + ifosfamide + Adriamycin) combined with regional hyperthermia in high-risk sarcoma: A pilot study. Cancer Chem Pharmacol. In press, 1993.Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Rolf D. Issels

There are no affiliations available

Personalised recommendations